Abstract
Medical care costing studies have excluded patients with a prior cancer history. This study aims to update methods for estimating medical care costs attributable to cancer and to evaluate the effect of a prior history of cancer on costs for colorectal cancer (CRC) patients. We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data and matched cancer patients to controls without cancer to estimate cancer-attributable costs by phases of care using Medicare 2007-2013 claims. CRC annualized average cancer-attributable costs were $56.0 K, $5.3 K, $92.5 K, and $24.3 K in the initial, continuing, and end-of-life cancer and noncancer death phases, respectively, in 2014 dollars. Costs were higher for patients diagnosed with more advanced stage, younger ages, and nonwhite races. Costs for patients with prior cancers were consistently higher than patients without prior cancers, especially in the continuing (4.9 K vs 7.2 K) and end-of-life noncancer death (22.7 K vs 30.0 K). Our CRC costs improve previous estimates by using more recent data and updated methods.
| Original language | English |
|---|---|
| Pages (from-to) | 22-30 |
| Number of pages | 9 |
| Journal | Journal of the National Cancer Institute - Monographs |
| Volume | 2020 |
| Issue number | 55 |
| DOIs | |
| Publication status | Published - 15 May 2020 |
Bibliographical note
Funding Information:This work was supported by the National Cancer Institute at the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institutes of Health, or the Centers for Medicare and Medicaid Services.
Publisher Copyright:
© 2020 Published by Oxford University Press. This work is written by US Government employees and is in the public domain in the US.